Mr. Thomas Smeenk reports

HEMOSTEMIX GRANTS STOCK OPTIONS

Hemostemix Inc., in accordance with its stock option plan, granted on Dec. 11, 2025, subject to regulatory approval, a total of 963,000 stock options to purchase common shares of Hemostemix to directors, officers, employees and consultants of Hemostemix.

Of the options granted, 663,000 vest immediately and 330,000 vest as to 50 per cent on Dec. 11, 2025, and 50 per cent on Dec. 11, 2026. All options were granted with an exercise price of nine cents per common share and have an expiry date of Dec. 11, 2030. After this option issuance, Hemostemix has 19,124,694 options issued and outstanding. Of the options granted, 663,000 options were issued to directors and officers of Hemostemix. Hemostemix relied on Section 5.5(b) of Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions, as the exemption from the formal valuation requirements of MI 61-101 and TSX Venture Exchange Policy 5.9 in respect of the option grant to the directors and officers of Hemostemix as no securities of Hemostemix are listed on a specified market as defined in MI 61-101. Hemostemix relied on Section 5.7(a) of MI 61-101 as the exemption from the minority approval requirements of MI 61-101 and TSX Venture Exchange Policy 5.9 in respect of the option grant to the directors and officers of Hemostemix as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the options granted to the directors and officers of the company exceeded 25 per cent of Hemostemix's market capitalization. The compensation committee and board of directors of the company have approved the option grant, and no materially contrary view or abstention was expressed or made by any director in relation to the option grant. The material change report to be filed in relation to the option grant will not be not filed at least 21 days prior to the completion of the option grant as contemplated by MI 61-101. The company believes that this shorter period is reasonable and necessary in the circumstances as the completion of the option grant occurred shortly before the issuance of this news release and the filing of such material change report.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed and patented, and is commercializing, its autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, the University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain, wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.